ClinicalTrials.gg
CompletedNCT05504967ORLUpdated Aug 15, 2025

CT Evaluating the Efficacy of Pre-incisional Local Analgesia With Ropivacaine + Dexamethasone in Pain Management After Tonsillectomy

A Phase 2 interventional study of Oradexon and Ropivacaine in Tonsillectomy, sponsored by Clinical Academic Center (2CA-Braga). Completed at 1 site in Portugal. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-08-15.

Sponsored by Clinical Academic Center (2CA-Braga) · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Dec 2020, registered May 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
115
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study is a randomized, controlled, double-blind clinical trial to evaluate the effect of local infiltration of ropivacaine and dexamethasone, alone or in association, in the reduction of pain and the need for supplementary analgesia, after tonsillectomy, in the immediate and late postoperative period, in individuals aged 18 to 65 years.

The present clinical trial will include 4 study groups, each with different content of infiltration into the amygdaline locus. One group will have ropivacaine in the infiltration, the other will have dexamethasone and another the association of these two drugs. In order to better understand the effectiveness of these drugs, there will also be a control group, in which saline solution will be infiltrated.

Approximately 104 individuals, aged 18 to 65 years, proposed for tonsillectomy will be included in the study, i.e., 26 subjects in each study group.

Postoperative pain will be characterized by self-assessment through the Visual Analog Scale (VAS, 100mm) at various moments of the study, namely in the preoperative consultation, in the pre-anesthetic consultation, at hospital admission and in the postoperative period until the 15th day after the surgery.

The aim of this study is not to eliminate intra and postoperative analgesia, but rather account for the need for analgesia depending on the different infiltration content peramygdalin. For this, in the postoperative period, a careful pain monitoring, having first-line analgesic and rescue medication for use immediate response in the face of minimal pain assessed by validated pain scales. It is intended, therefore, to record which analgesic drugs and in what doses were necessary.

02

Conditions studied

  • Tonsillectomy

Keywords

  • Tonsillectomy
  • Pain management
03

In context

Lead sponsor

Clinical Academic Center (2CA-Braga) is the lead sponsor of 7 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ASA) physical status I-II;
  • Surgical proposal of tonsillectomy;
  • Tonsillectomy performed by the cold shedding technique;
  • History of recurrent tonsillitis, caseous tonsillitis and / or peritonsillar abscess;

Exclusion criteria

Exclusion Criteria:

  • Use of chronic analgesic medication;
  • ;
  • Coagulation disorders, such as von Willebrand disease or diagnosis of other disorders, haemophilia A and B, or diseases that may develop with hemostatic dysfunction;
  • Intolerance or allergy to any of the drugs used in the study;
  • Suspicious or confirmed diagnosis of neoplastic disease;
  • Fever or acute respiratory tract infection in the last 3 weeks;
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
115 participants (actual)

Study arms

  • Active comparator
    dexamethasone

    12.5mg dexamethasone + saline solution peramygdalin infiltration in each loca (25mg in total). Single dosage pre-incisional.

    Drug: Oradexon · Drug: Saline solution

  • Active comparator
    ropivacain

    18.75 mg ropivacain + saline solution peramygdalin infiltration in each loca (37mg in total). Single dosage pre-incisional.

    Drug: Ropivacaine · Drug: Saline solution

  • Experimental
    ropivacain + dexamethasone

    18.75mg ropivacain + 12.5mg dexamethasone peramygdalin infiltration (in each loca). Single dosage pre-incisional.

    Drug: Oradexon · Drug: Ropivacaine

  • Placebo comparator
    placebo

    Saline solution (NaCl 0.9%) peramygdalin infiltration (in each loca). Single dosage pre-incisional. 4 syringes must be prepared, two for each of the tonsil sites.

    Drug: Saline solution

Interventions

  • DrugDexamethasone phosphateStudies of Dexamethasone phosphateDexamethasone phosphate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    With a syringe aspirate 2.5 ml of a 5mg/ml dexamethasone solution, for a total of 12.5mg. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.

    Also known as: dexamethasone

  • With a syringe aspirate 2.5 ml of a 7.5mg/ml dexamethasone solution, for a total of 18.75mg. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.

  • DrugSaline solution

    With a syringe, aspirate 2.5 ml of a 0.9% NaCl solution. Repeat the procedure with another syringe. 2 syringes must be prepared, one for each of the tonsil sites.

06

What researchers measure

Primary outcomes

  1. Change in pain assessment using the VAS

    Alteration in Visual Analogue Scale values (1-100mm) to assess pain at rest and during swallowing

    Time frame: Change from baseline (90 days before surgery; day of surgery, day 1, 2, 3, 7 and 15 after surgery)

  2. Time to first administration of analgesia

    Time until it is needed to administer analgesia to the patient, after surgery (in minutes)

    Time frame: From the day of surgery to discharge (an average 1 day)

  3. Paracetamol intake

    Number of paracetamol intakes

    Time frame: Time since the end of surgery until post-operative visit (15 days after surgery)

  4. Paracetamol cumulative dosage intake

    Cumulative dosage of paracetamol intake in mg

    Time frame: Time since the end of surgery until post-operative visit (15 days after surgery)

  5. Rescue analgesia intake

    Number of rescue analgesia intakes (tramadol)

    Time frame: Time since the end of surgery until post-operative visit (15 days after surgery)

  6. Need of Pethidine

    Need of pethidine in immediate post-surgery (yes/no)

    Time frame: Immediate post-surgery

  7. Time to need of Pethidine

    Time until pethidine admnistration is needed, since the end of surgery (minutes)

    Time frame: Time since the end of surgery until post-operative visit (15 days after surgery)

  8. Time to onset of water intake, liquid and solid oral diet

    Time to onset of water intake, liquid and solid oral diet, since the end of surgery (minutes)

    Time frame: Time since the end of surgery until post-operative visit (15 days after surgery)

Secondary outcomes

  1. Safety outcome

    Number of adverse events

    Time frame: Time since screening until post-operative visit (15 days after surgery)

07

Study locations

1 site
  • Serviço de Otorrinolaringologia, Hospital de Braga
    Braga, 4710-243, Portugal
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Jul 2023, 30 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2022
First posted
Aug 17, 2022
StartActual
Dec 22, 2020
Primary completionActual
Jul 1, 2023
CompletionActual
Jul 1, 2023
Last update
Aug 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05504967
Lead sponsor
Clinical Academic Center (2CA-Braga)
Responsible party
Sponsor
First posted
Aug 17, 2022
Start date
Dec 22, 2020
Primary completion
Jul 1, 2023
Completion
Jul 1, 2023
Last update
Aug 15, 2025

Study contacts

Ana Menezes
principal investigator · Serviço de Otorrinolaringologia, Hospital de Braga, EPE

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dexamethasone phosphate · Ropivacaine

Start the discussion